Contrast-Enhanced 3D-FLAIR Imaging of the Optic Nerve and Optic Nerve Head: Novel Neuroimaging Findings of Idiopathic Intracranial Hypertension.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
02 2019
Historique:
received: 02 08 2018
accepted: 23 11 2018
pubmed: 27 1 2019
medline: 3 3 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

The sensitivity of contrast-enhanced 3D-FLAIR has not been assessed in patients with idiopathic intracranial hypertension. The purpose of this study was to evaluate whether hyperintensity of the optic nerve/optic nerve head on contrast-enhanced 3D-FLAIR imaging is associated with papilledema in patients with idiopathic intracranial hypertension. A retrospective review was conducted from 2012 to 2015 of patients with clinically diagnosed idiopathic intracranial hypertension and age- and sex-matched controls who had MR imaging with contrast-enhanced 3D-FLAIR. Two neuroradiologists graded each optic nerve/optic nerve head on a scale of 0-3. This grade was then correlated with the Frisén Scale, an ophthalmologic scale used for grading papilledema from 0 (normal) to 5 (severe edema). To estimate the correlation between the MR imaging and Frisén scores, we calculated the Kendall τ coefficient. Forty-six patients (3 men, 43 women) with idiopathic intracranial hypertension and 61 controls (5 men, 56 women) with normal findings on MR imaging were included in this study. For both eyes, there was moderate correlation between the 2 scales (right eye: τ = 0.47; 95% CI, 0.31-0.57; left eye: τ = 0.38; 95% CI, 0.24-0.49). Interreader reliability for MR imaging scores showed high interreader reliability (right eye: κ = 0.76; 95% CI, 0.55-0.88; left eye: κ = 0.87; 95% CI, 0.78-0.94). Contrast-enhanced 3D-FLAIR imaging correlates with the Frisén Scale for moderate-to-severe papilledema and less so for mild papilledema. Hyperintensity of the optic nerve/optic nerve head on contrast-enhanced 3D-FLAIR is sensitive for the detection of papilledema in patients with idiopathic intracranial hypertension, which may be useful when prompt diagnosis is crucial.

Sections du résumé

BACKGROUND AND PURPOSE
The sensitivity of contrast-enhanced 3D-FLAIR has not been assessed in patients with idiopathic intracranial hypertension. The purpose of this study was to evaluate whether hyperintensity of the optic nerve/optic nerve head on contrast-enhanced 3D-FLAIR imaging is associated with papilledema in patients with idiopathic intracranial hypertension.
MATERIALS AND METHODS
A retrospective review was conducted from 2012 to 2015 of patients with clinically diagnosed idiopathic intracranial hypertension and age- and sex-matched controls who had MR imaging with contrast-enhanced 3D-FLAIR. Two neuroradiologists graded each optic nerve/optic nerve head on a scale of 0-3. This grade was then correlated with the Frisén Scale, an ophthalmologic scale used for grading papilledema from 0 (normal) to 5 (severe edema). To estimate the correlation between the MR imaging and Frisén scores, we calculated the Kendall τ coefficient.
RESULTS
Forty-six patients (3 men, 43 women) with idiopathic intracranial hypertension and 61 controls (5 men, 56 women) with normal findings on MR imaging were included in this study. For both eyes, there was moderate correlation between the 2 scales (right eye: τ = 0.47; 95% CI, 0.31-0.57; left eye: τ = 0.38; 95% CI, 0.24-0.49). Interreader reliability for MR imaging scores showed high interreader reliability (right eye: κ = 0.76; 95% CI, 0.55-0.88; left eye: κ = 0.87; 95% CI, 0.78-0.94). Contrast-enhanced 3D-FLAIR imaging correlates with the Frisén Scale for moderate-to-severe papilledema and less so for mild papilledema.
CONCLUSIONS
Hyperintensity of the optic nerve/optic nerve head on contrast-enhanced 3D-FLAIR is sensitive for the detection of papilledema in patients with idiopathic intracranial hypertension, which may be useful when prompt diagnosis is crucial.

Identifiants

pubmed: 30679213
pii: ajnr.A5937
doi: 10.3174/ajnr.A5937
pmc: PMC6375763
mid: NIHMS1515827
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-339

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR002374
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 by American Journal of Neuroradiology.

Références

J Neuroophthalmol. 2014 Dec;34(4):331-5
pubmed: 25000261
Br J Ophthalmol. 1981 Nov;65(11):767-77
pubmed: 6173060
Neurol Clin. 2010 Aug;28(3):593-617
pubmed: 20637991
Ophthalmology. 1998 Sep;105(9):1686-93
pubmed: 9754178
Clin Neurol Neurosurg. 2015 Oct;137:94-101
pubmed: 26164677
Neuroradiology. 1995 Aug;37(6):459-61
pubmed: 7477858
Invest Ophthalmol Vis Sci. 1998 Jan;39(1):134-42
pubmed: 9430554
Eur J Radiol Open. 2017 Feb 28;4:13-18
pubmed: 28275657
AJNR Am J Neuroradiol. 2017 Sep;38(9):1789-1793
pubmed: 28663268
AJNR Am J Neuroradiol. 2011 Feb;32(2):301-5
pubmed: 21183615
AJNR Am J Neuroradiol. 2013 Jul;34(7):1438-42
pubmed: 23370477
Prog Retin Eye Res. 2016 Jan;50:108-44
pubmed: 26453995
Prog Retin Eye Res. 2015 May;46:67-83
pubmed: 25619727
Arch Neurol. 1982 Aug;39(8):461-74
pubmed: 7103794
Mult Scler. 2019 May;25(6):792-800
pubmed: 29683029
JAMA Neurol. 2013 Jul;70(7):937-8
pubmed: 23712534
J Neuroophthalmol. 2017 Mar;37(1):3-6
pubmed: 28187078
Arch Ophthalmol. 1977 Aug;95(8):1458-62
pubmed: 70201
J Neuroophthalmol. 2011 Jun;31(2):175-86
pubmed: 21593630
Semin Neurol. 2015 Oct;35(5):527-38
pubmed: 26444398
J Neurol Sci. 2013 Sep 15;332(1-2):80-5
pubmed: 23850064
Clin Exp Ophthalmol. 2009 Jul;37(5):444-7
pubmed: 19624339
Neuroradiology. 2006 Aug;48(8):521-7
pubmed: 16703359
Pediatr Neurol. 2015 Aug;53(2):151-6
pubmed: 26101095
AJNR Am J Neuroradiol. 2017 Mar;38(3):471-477
pubmed: 28104635
JAMA Neurol. 2014 Jun;71(6):693-701
pubmed: 24756302
AJNR Am J Neuroradiol. 2011 Dec;32(11):1986-93
pubmed: 21680652
Brain. 2007 Feb;130(Pt 2):514-20
pubmed: 17114796

Auteurs

E Golden (E)

From the Departments of Radiology (E.G., J.-P.J.Y., T.A.K.).

R Krivochenitser (R)

Ophthalmology (R.K., N.M., Y.C.).

N Mathews (N)

Ophthalmology (R.K., N.M., Y.C.).

C Longhurst (C)

Department of Biostatistics and Medical Informatics (C.L.).

Y Chen (Y)

Ophthalmology (R.K., N.M., Y.C.).

J-P J Yu (JJ)

From the Departments of Radiology (E.G., J.-P.J.Y., T.A.K.).
Psychiatry (J.-P.J.Y.), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Department of Biomedical Engineering (J.-P.J.Y.), College of Engineering.
Neuroscience Training Program (J.-P.J.Y.), Wisconsin Institutes for Medical Research, University of Wisconsin-Madison, Madison, Wisconsin.

T A Kennedy (TA)

From the Departments of Radiology (E.G., J.-P.J.Y., T.A.K.) tkennedy@uwhealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH